HC Wainwright & Co. analyst Raghuram Selvaraju downgrades ObsEva (NASDAQ:OBSV) from Buy to Neutral.
Roche Buys Pfizer & Roivant Sciences’ Televant In ~$7.1B Deal
Roche Holding AG (OTC: RHHBY) inked a deal to acquire
HC Wainwright & Co. Downgrades ObsEva to Neutral
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades ObsEva (NASDAQ:OBSV) from Buy to Neutral.
Related Posts
Oppenheimer Maintains Outperform Rating for Prometheus Biosciences: Here’s What You Need To Know
Oppenheimer has decided to maintain its Outperform rating of Prometheus Biosciences (NASDAQ:RXDX) and raise its price target from $50.00 to $65.00.
Shares of Prometheus Biosciences are trading down 0.17% over the last 24 hours, at $59.90 per share.
Morgan Stanley Maintains Equal-Weight on Life Time Group Hldgs, Lowers Price Target to $16
Morgan Stanley analyst Brian Harbour maintains Life Time Group Hldgs (NYSE:LTH) with a Equal-Weight and lowers the price target from $17 to $16.
Gracell Biotechnologies To Present Data Highlighting Preclinical Efficacy Of SMART CART Against Solid Tumors At Society For Immunotherapy Of Cancer 38th Annual Meeting
Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained